+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North American Anticoagulants Market 2020-2026

  • ID: 5240817
  • Report
  • January 2021
  • Region: North America, United States
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021
1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Baxter International Inc.
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MORE
North American Anticoagulants Market Size, Share & Trends Analysis Report, By Type (Novel Oral Anticoagulants, Vitamin K Antagonist, and Heparin and Low Molecular Weight Heparin), By Application (Pulmonary Embolism, Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis, and Others) and Forecast, 2020-2026.

North American anticoagulants market is estimated to grow at a CAGR of 7.2% during the forecast period. Some pivotal factors encouraging the market growth include the rising prevalence of heart diseases and increasing FDA approvals for anticoagulants drugs. As per the Centers for Disease Control and Prevention (CDC), in the US, someone has a heart attack every 40 seconds. This is leading to an increasing demand for anticoagulants that are known as blood thinners. It supports prevention of blood clots and are recommended for people who at a high risk of getting clots. It aims to decrease their possibility of developing severe conditions including heart attacks and strokes.

The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). A vitamin K antagonist is utilized for the treatment of thromboembolism with cardiac valve replacement, thromboembolic events post myocardial infarction, venous thromboembolism, pulmonary embolism, and thromboembolism with atrial fibrillation. In vitamin K antagonist (VKA) anticoagulant, warfarin is the most commonly utilized medication in the US to reduce the risk of stroke in certain atrial fibrillation patients with risk factors. Based on application, the market is classified into pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others.

Some prominent players in the market include Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. The market players are using some key strategies to increase their market share. For instance, in December 2019, the US FDA approved two applications for the first generics of Eliquis (apixaban) tablets. These medications are intended to minimize the chances of systemic embolism and stroke in patients who are suffering from nonvalvular atrial fibrillation. This drug is also intended for prophylaxis of deep vein thrombosis (DVT), which may result in pulmonary embolism (PE), in patients who have experienced hip or knee replacement surgery. The approval of the generic apixaban is granted to Mylan Pharmaceuticals Inc. and Micro Labs Ltd.

Research Methodology

The market study of the North American anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. North American Anticoagulants Market Research and Analysis by Type
2. North American Anticoagulants Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the North American anticoagulants market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American anticoagulants market.
  • Insights about market determinants that are stimulating the North American anticoagulants market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Baxter International Inc.
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. North AmericanAnticoagulants Market by Type
5.1.1. Novel Oral Anticoagulants (NOACs)
5.1.2. Vitamin K Antagonist
5.1.3. Heparin and Low Molecular Weight Heparin (LMWH)
5.2. North AmericanAnticoagulants Market by Application
5.2.1. Pulmonary Embolism
5.2.2. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
5.2.3. Deep Vein Thrombosis (DVT)
5.2.4. Others

6. Regional Analysis
6.1. United States
6.2. Canada

7. Company Profiles
7.1. Abbott Laboratories
7.2. Baxter International Inc.
7.3. Boehringer Ingelheim GmbH
7.4. Bristol Myers Squibb Co.
7.5. Daiichi Sankyo Company, Ltd.
7.6. Johnson & Johnson Services, Inc.
7.7. Merck & Co., Inc.
7.8. Mylan N.V.
7.9. Pfizer Inc.
7.10. Portola Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
3 of 3
  • Abbott Laboratories
  • Baxter International Inc.
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Company, Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll